Welcome to the ALIAS2 study site!
The ALIAS2 study is a Phase III Randomized Multicenter clinical trial.
This study is conducted to ascertain whether high-dose human albumin therapy
confers neuroprotection in acute ischemic stroke.
The ALIAS2 trial is supported with a web-based clinical trial data management
To enter the WebDCU™ data management system, click on the button below.
A user ID and password are required to access this system.